Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | STS | P08842 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16662147 | 0.88 | LMNA (0.47) | KMT2ASLC18A3PTPN2PTPN1PTPN6 | |
| SCHEMBL29480691 | 0.87 | KMT2A (0.51) | KMT2APTPN2PTPN1PTPN6ABL1 | |
| SCHEMBL21795781 | 0.87 | KMT2A (0.51) | KMT2APTPN2PTPN1PTPN6ABL1 | |
| SCHEMBL9980757 | 0.86 | GPR119 (0.62) | KMT2ASLC18A3PTPN2PTPN1PTPN6 | |
| SCHEMBL16632062 | 0.85 | STS (0.51) | KMT2APTPN2PTPN1PTPN6ABL1 | |
| SCHEMBL14113587 | 0.83 | KMT2A (0.71) | KMT2APTPN2PTPN1PTPN6ABL1 | |
| SCHEMBL408202 | 0.83 | GPR119 (0.63) | KMT2ASLC18A3PTPN2PTPN1PTPN6 | |
| SCHEMBL21605851 | 0.81 | GPR119 (0.55) | KMT2APTPN2PTPN1PTPN6GPR119 | |
| SCHEMBL13391294 | 0.80 | GPR119 (0.59) | KMT2ASLC18A3PTPN2PTPN1PTPN6 | |
| SCHEMBL24833605 | 0.80 | MGLL (0.56) | KMT2ASLC18A3PTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | SIGMAR1, TMEM97, OPRM1 | KMT2A 3940/4885SLC18A3 248/4885PTPN2 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.